Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNS8801 With and Without Pembrolizumab in Treatment-Refractory Melanoma
NCT06624644Phase 3Recruiting
- Sponsor
- Linnaeus Therapeutics
- Start
- Aug 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lns-8801 in cutaneous melanoma (CM), sponsored by Linnaeus Therapeutics. Started Aug 2025; status: recruiting.
02
Drugs
lns-8801
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT06624644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624644.